single20MG
Prostamax
20MG Protocol
Prostamax 20MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks; optional extension to 16 weeks
Reconstitution
2.0 mL BAC water
Reduced inflammation and fibrosis markers in preclinical prostatitis models
Favorable prostate histology/weight parameters in BPH models
Epigenetic/gene-regulatory mechanism proposed for short bioregulatory peptides
Generally favorable tolerability described in preclinical settings
1
Reconstitution Requirements
- 2.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 500 mcg (0.5 mg) | 5 |
| 2 | Weeks 3–4 | 750 mcg (0.75 mg) | 7.5 |
| 3 | Weeks 5–8 | 1,000 mcg (1 mg) | 10 |
| 4 | Weeks 9–12 | 1,000 mcg (1 mg) | 10 |
Inject once daily
8–12 weeks; optional extension to 16 weeks
Prostamax (KEDP; Lys–Glu–Asp–Pro) is presented as a short bioregulatory peptide derived from prostate tissue peptide-complex research and studied in preclinical models of prostate inflammation and hyperplasia. Mechanistically, the protocol frames KEDP-class peptides as epigenetic-style gene regulators that may interact with chromatin structure and histone proteins, influencing which genes are active or silenced. The page cites observations in aged human lymphocytes where KEDP was associated with pericentromeric chromatin decondensation, interpreted as potential gene-reactivation signaling. In rat prostatitis models summarized by the protocol, intramuscular administration is described as reducing inflammatory markers and helping prevent fibrotic changes in prostate tissue; in BPH models, favorable effects on prostate weight and histologic parameters are described. Overall, Prostamax is positioned as an investigational peptide that may modulate inflammatory and tissue-remodeling programs via gene-expression regulation, with human trial evidence not yet available.
Mild injection-site reactions (redness/tenderness)
Limited human clinical data (no published human trials described)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)